| Accession |
PRJCA012402 |
| Title |
Glumetinib (SCC244), a Selective MET Inhibitor in Patients with Advanced Non-Small Cell Lung Cancer Harboring MET-alterations |
| Relevance |
Medical |
| Data types |
Biomarker
|
| Organisms |
Homo sapiens
|
| Description |
This is an open-label, multicenter phase Ib/II study including two parts: Phase Ib in NSCLC patients with MET-aberrations and Phase II in patients with locally advanced or metastatic NSCLC (stage IIIb,IIIc or IV) harboring METex14 skipping mutation. |
| Sample scope |
Multiisolate |
| Release date |
2024-10-10 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Haihe Biopharma Co., Ltd.
|
NA
|
2017L00084
|
|
|
|
| Submitter |
shun
Lu (shunlu_shchest@sina.com)
|
| Organization |
Shanghai Chest Hospital |
| Submission date |
2022-10-10 |
